Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor

Allosteric, covalent inhibitor ALTA-2618 selectively and potently inhibits AKT1 E17K mediated cellular functions

Strong anti-tumor activity against AKT1 E17K expressing PDX models and favorable pharmacokinetic properties demonstrated

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers. The data are being presented in a poster presentation on April 8^th at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA on April 5-10, 2024.

ALTA-2618 is an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K. AKT1 E17K is a clinically validated oncogene that drives cancers, including breast, endometrial, and prostate cancers. This program is designed for patients with limited treatment options and is expected to begin clinical testing in the next year.

“We’re excited to present data at AACR featuring Alterome’s lead program, ALTA-2618, the first AKT1 E17K-selective inhibitor. We believe this data provides validation of the strong dependence of certain cancers on this mutation and underscores the high impact a selective inhibitor could achieve with continuous target coverage,” said Eric Murphy, Ph.D., co-founder and CEO of Alterome Therapeutics. “This work was an important step forward in Alterome’s mission to discover precise therapies that generate preclinical tumor regressions with improved safety profiles, and supports the advancement of ALTA-2618 into first-in-human clinical trials in 2024.”

Key Findings:

• ALTA-2618 is the first allosteric & mutant-selective drug for AKT1 E17K driven cancers.
• ALTA-2618 has favorable pharmacokinetic properties across multiple preclinical species.
• ALTA-2618 is well tolerated with daily oral dosing in tumor-bearing mice.
• The compound demonstrated significant anti-tumor effects in clinically-relevant PDX models driven by AKT1 E17K.
• No on-target toxicities (e.g., hyperglycemia) are observed with daily ALTA-2618 treatment.

Poster Presentation Details:

Title: Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Date and Time: Monday, April 8 from 1:30 p.m. – 5:00 p.m. PT
Abstract Number: LB173 / 19
Speaker/Lead Author: Tim Sen Wang, Ph.D., Alterome Therapeutics

About Alterome Therapeutics, Inc.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is led by an expert team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.

For more information, visit www.alterome.com.

Follow us on LinkedIn and Twitter.